Direct cost for initial management of prostate cancer: A systematic review

Current Oncology

Volumn 20, Issue 6, 2013, Pages

  Sanyal, C ^a,b   Aprikian, A G ^a,b   Chevalier, S ^a,b   Cury, F L ^c   Dragomir, A ^a,b  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Direct costs; Economic burden; Health policy; Prostate cancer; Systematic review

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DISEASE SURVEILLANCE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; PREVALENCE; PROSTATE CANCER; QUALITY CONTROL; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84890091432     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1630     Document Type: Article

References (48)

1. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society; 2011.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. [Erratum in: CA Cancer J Clin 2011;61:133-4]
3. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005;11:437-41.
4. Quon H, Loblaw A, Nam R. Dramatic increase in prostate cancer cases by 2021. BJU Int 2011;108:1734-8.
5. National Comprehensive Cancer Network (nccn). NCCN Guidelines for Patients: Prostate Cancer. Ver. 1.2013. Fort Washington, PA: nccn; 2013. [Available online at: http:// www.nccn.org/patients/guidelines/prostate/index.html; cited May 19, 2013]
6. Heidenreich A, Bellmunt J, Bolla M, et al. on behalf of the European Association of Urology. eau guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
7. Grover SA, Coupal L, Zowall H, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ 2000;162:987-92.
8. Health Canada, Population and Public Health Branch, Strategic Policy Directorate, Policy Research Division. Economic Burden of Illness in Canada, 1998. Ottawa, ON: Health Canada; 2002. [Available online at http://publications.gc.ca/collections/ Collection/H21-136-1998E.pdf; cited October 18, 2012]
9. Krahn MD, Zagorski B, Laporte A, et al. Healthcare costs associated with prostate cancer: estimates from a populationbased study. BJU Int 2010;105:338-46.
10. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995;33:828-41.
11. Druss BG, Marcus SC, Olfson M, Pincus HA. The most expensive medical conditions in America. Health Aff (Millwood) 2002;21:105-11.
12. Pagano E, Brunetti M, Tediosi F, Garattini L. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics 1999;15:583-95.
13. Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001;19:207-13.
14. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33.
15. Tarride JE, Lim M, DesMeules M, et al. A review of the cost of cardiovascular disease. Can J Cardiol 2009;25:195-202.
16. Shemilt I, Mugford M, Byford S, et al. Chapter 15: incorporating economics evidence. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Ver. 5.0.1. Oxford, UK: The Cochrane Collaboration; 2008. [Current version available online at: http://www.cochranehandbook. org; cited May 19, 2013]
17. Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial fibrillation. Value Health 2012;15:240-8.
18. Organisation for Economic Co-operation and Development (oecd), StatExtracts. 4. PPPs and exchange rates [Web resource]. Paris, France: oecd; n.d. [Available at: http://stats. oecd.org/Index.aspx?datasetcode=SNA_TABLE4; cited May 19, 2013]
19. OANDA Corporation. Currency Converter [Web resource]. New York, NY: OANDA Corporation; n.d. [Available at: http://www.oanda.com/ (click "Currency Converter"); cited May 19, 2013]
20. Statistics Canada. Home > CANSIM. Table 326-0021 Consumer Price Index (CPI), 2009 basket annual (2002=100) [Web resource]. Ottawa, ON: Statistics Canada; 2013. [Available at: http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang= eng&id=3260021&paSer=&pattern=&stByVal=1&p1=1&p2= 37&tabMode=dataTable&csid=; cited May 19, 2013]
21. Drummond MF, Sculpher MJ, Torrance G, O'Brien B, Stoddart G. Methods for the Economic Evaluation of Health Care Programs. 3rd ed. Oxford, UK: Oxford University Press; 1997.
22. Jonsson L, Wimo A. The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics 2009;27:391-403.
23. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France. Curr Med Res Opin 2005;21:1617-29.
24. Benoit RM, Cohen JK, Miller RJ Jr. Comparison of the hospital costs for radical prostatectomy and cryosurgical ablation of the prostate. Urology 1998;52:820-4.
25. Wagner TT 3rd, Young D, Bahnson RR. Charge and length of hospital stay analysis of radical retropubic prostatectomy and transperineal prostate brachytherapy. J Urol 1999;161:1216-18.
26. Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 2000;89:1792-9.
27. Kohan AD, Armenakas NA, Fracchia JA. The perioperative charge equivalence of interstitial brachytherapy and radical prostatectomy with 1-year followup. J Urol 2000;163:511-14.
28. Penson DF, Schonfeld WH, Flanders SC, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the capsure database. Urology 2001;57:499-503.
29. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol 2002;20:2869-75.
30. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment. Cancer 2012;118:3512-18.
31. Makhlouf AA, Boyd JC, Chapman TN, Theodorescu D. Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology 2002;60:656-60.
32. Mouraviev V, Nosnik I, Sun L, et al. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology 2007;69:311-14.
33. Wilson LS, Tesoro R, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007;109:518-27.
34. Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010;13:162-7.
35. Fourcade RO, Benedict A, Black LK, Stokes ME, Alcaraz A, Castro R. Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK. BJU Int 2010;105:49-56.
36. Eldefrawy A, Katkoori D, Abramowitz M, Soloway MS, Manoharan M. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison. Urol Oncol 2013;31:576-80.
37. Molinier L, Castelli C, Bauvin E, et al. Cost study of the clinical management of prostate cancer in France: results on the basis of population-based data. Eur J Health Econ 2011;12:363-71.
38. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011;29:1517-24.
39. Lowrance WT, Eastham JA, Yee DS, et al. Costs of medical care after open or minimally invasive prostate cancer surgery: a population-based analysis. Cancer 2012;118:3079-86.
40. Tomaszewski JJ, Matchett JC, Davies BJ, Jackman SV, Hrebinko RL, Nelson JB. Comparative hospital cost-analysis of open and robotic-assisted radical prostatectomy. Urology 2012;80:126-9.
41. Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 2011;29:653-71.
42. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006;77:51-63.
43. Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care 1999;37:436-44.
44. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 1994;18:796-803.
45. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997;157:559-62.
46. Spires SE, Cibull ML, Wood DP Jr, Miller S, Spires SM, Banks ER. Gleason histologic grading in prostatic carcinoma. Correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 1994;118:705-8.
47. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566-76.
48. Palmer S, Byford S, Raftery J. Economics notes: types of economic evaluation. BMJ 1999;318:1349.